Blog

Latest news about encapsia

Home Visit app to optimize virtual clinical trials

Written by Cmed
07 May 2020

Cmed Technology announced today the encapsia Home Visit app is now available to capture and manage clinical trial data from patients at home or in the community. The app works seamlessly with all the other encapsia apps, including web EDC (Entry app) and direct data capture (esource app) to provide tremendous flexibility in the choice of data capture methods both before and during a study. This helps maintain patient participation and clinical data flow which is particularly compelling to minimize disruption during the COVID-19 pandemic as well as in the new landscape for clinical trials that is expected to follow.

Supplementing or replacing site visits with home visits by nurses allows more patients to be included in clinical trials. For some trials, all assessments can be conducted outside a hospital or clinic while in other trials the number of visits to the hospital or clinic may be reduced. The technology has obvious benefits for very many patients, especially those who are ill or elderly and unable to travel. It may also make patient enrolment easier, faster and more representative of the patient population.

The Home Visit app does not need bespoke hardware, avoiding problems of sourcing and logistics. The Home Visit app is simply downloaded onto a standard iPad and will work in locations without internet access, automatically and seamlessly resynchronizing with the cloud-hosted encapsia servers when a connection is available. The app will guide the study nurse in the accurate and complete capture of clinical trial data with all edit checks firing on entry of data (as in the other encapsia apps). In addition, the encapsia Home Visit app can also provide the nurse with access to other vital patient data such as laboratory reports and study documentation.

Encapsia is powered by a full cloud architecture to enable the collection of all types of clinical trial data from multiple sources into a single data repository and using a single configuration. This structure means any mix of home captured, EDC, eSource, lab data reports or data from wearables is collected into the same data repository and all displayed through sophisticated live visualizations that can be acted upon inside the system. In the same way, encapsia integrates with other information systems including ePRO, eCOA and IRT for real-time visibility of all trial data and streamlined patient interactions.

Dr Timothy Corbett-Clark, Cmed Chief Technology Officer commented, “Recent events have brought the shortcomings of current EDC solutions into industry awareness. Their age and a history of “bolting together” different technologies and products has created inflexible solutions that are struggling to adapt to a changing world. Many people working in clinical trials wanted and needed better approaches but change wasn’t given the priority it needed - until now. The future has arrived sooner than expected, so it’s up to us to make something good come out of this.”

The Home Visit app, like esource and Entry apps, also works with the Randomization and Inventory apps of encapsia to support seamless requests for drug dispensation, perform drug accountability and randomization.

Encapsia is available with CRO or data analytics services via Cmed Clinical Services or as software as a service from Cmed Technology.



To talk to our team about how Cmed supports decentralized trials, please contact in the first instance:

In North America: Jay Conze jconze@cmedresearch.com
In the rest of the world: Maria Iliescu miliescu@cmedresearch.com


Last 3 posts

Each year we eagerly await the kick-off to the conference season with Arena’s Outsourcing in Clinical Trials (OCT) West Coast event. The conference brings together biotech and pharmaceutical clinical operations, outsourcing and procurement management, while showcasing innovations and technological advancements in the clinical trial space. This year was no exception and although the event was virtual, OCT West Coast managed to gather over 800 clinical trial professionals, looking to meet their peers and share insights into how we can conduct clinical trials of the future.
Running a rare disease study includes many challenges. It’s a more difficult patient population to access which leads to difficulties in patient recruitment, fewer medical experts available, navigation through often complex regulations, as well as potentially complex study designs. This small population makes these studies expensive as you need more sites, maybe across more countries with more time in conduct to achieve your recruitment targets – resulting in costly set-up, management and monitoring of your study.
Modern technologies support agile processes for clinical trials 95% of attendees to our webinar this week agreed with the central message that processes and supporting technologies commonly used in clinical trials are outdated, and furthermore they contributed to the huge disruption of clinical trials caused by the COVID-19 pandemic. Systems and methods for data collection, monitoring, review and analysis have evolved in a piecemeal fashion, and whether well suited or not, are normally “bolted together”.